CONTROVERSIES IN THE MANAGEMENT OF HEAD AND NECK CANCER PROVISIONAL PROGRAMME



*Please note that speakers are invited and pending confirmation

WEDNESDAY 15TH MAY 2019

10.00	IMPLICATIONS OF CHANGES IN TNM 8 TH EDITION Implications of TNM 8 changes for the surgical oncologist (OPC pTNM and oral clinical TNM)	Andreas Dietz
10.15	Implications of TNM 8 changes for the radiation and medical oncologist	Mererid Evans
10.30	Discussion	
10.45	EMERGING AREAS OF PRACTICE Key note: Indications for proton therapy in head and neck cancer – An update	Hans Langendijk
11.15	An evidence based approach for the investigation and management of occult carcinoma of unknown primary	Hisham Mehanna
11.30	Sentinel node update – The UK experience	Claire Schilling
11.45	Key note: Supracricoid and supracricotracheal laryngectomy – Indications and contra indications in routine clinical practice	Dominique Chevalier
12.15	Management of challenging cases - Larynx and hypopharynx	Moderator: Stuart Winter
12.15 13.30		Moderator: Stuart Winter
	- Larynx and hypopharynx	Moderator: Stuart Winter Wojciech Golusinski
13.30	- Larynx and hypopharynx Lunch and exhibition PREVENTING AND TREATING COMPLICATIONS Enhanced recovery intra and post operatively for surgical	
13.30 14.15	- Larynx and hypopharynx Lunch and exhibition PREVENTING AND TREATING COMPLICATIONS Enhanced recovery intra and post operatively for surgical patients	Wojciech Golusinski
13.30 14.15 14.30	- Larynx and hypopharynx Lunch and exhibition PREVENTING AND TREATING COMPLICATIONS Enhanced recovery intra and post operatively for surgical patients Human factors in the treatment of HNC Prophylactic swallowing exercise programmes pre	Wojciech Golusinski Peter Brennan
13.30 14.15 14.30 14.45	- Larynx and hypopharynx Lunch and exhibition PREVENTING AND TREATING COMPLICATIONS Enhanced recovery intra and post operatively for surgical patients Human factors in the treatment of HNC Prophylactic swallowing exercise programmes pre chemoradiotherapy – Why, when and how	Wojciech Golusinski Peter Brennan Justin Roe

CONTROVERSIES IN THE MANAGEMENT OF HEAD AND NECK CANCER PROVISIONAL PROGRAMME



*Please note that speakers are invited and pending confirmation

16.15 Management of challenging cases

- Oral, sinus and salivary disease

17.45 Close of day 1

Moderator: Cyrus Kerawala

THURSDAY 16TH MAY 2019

09.15	ADVANCES IN HPV POSITIVE HEAD AND NECK CANCER MANAGER Patients with equivocal PET scans post CRT – Neck dissection or not?	<mark>MENT</mark> Paul Nankivell
09.30	The role of circulating DNA in the surveillance of HPV positive head and neck cancer recurrence	Shree Bhide
09.45	The use of p16 for treatment selection – Could we be harming our patients?	Selvam Thavaraj
10.00	Discussion	
10.15	Management of challenging cases - Oropharyngeal and occult primary	Moderator: Vinidh Paleri
11.45	IMPROVING OUTCOMES FOR ELDERLY PATIENTS Models for selection for treatment in the elderly patients	Petr Szturz
12.00	Optimising elderly patients for head and neck cancer treatment – The GOLD clinic	Tania Kalsi
12.15	Surgical treatment of head and neck cancer in elderly patients – Patient selection	Jarrod Homer
12.30	Palliative radiotherapy for elderly patients – Why, when and how?	Charles Kelly
12.45	Discussion	
13.00	Lunch and exhibition	
13.45	IMPROVING OUTCOMES FOR RECURRENCE PATIENTS Better selection for patients for salvage surgery	Rene Leemans
14.00	Practical tips and tricks for improving outcomes of salvage surgery	Sefik Hosal

CONTROVERSIES IN THE MANAGEMENT OF HEAD AND NECK CANCER PROVISIONAL PROGRAMME



*Please note that speakers are invited and pending confirmation

14.15	Improving outcomes and patient selection for re-irradiation for head and neck cancer recurrence	Yungan Tao
14.30	The role of Boron Neutron Capture Therapy (BNCT) therapy in the treatment of head and neck cancer recurrence	Leena Kankaanranta
14.45	Key note: How can we balance rising costs with the need for new treatments.	John A. Ridge
15.15	Discussion	
15.30	CANCER AND THE IMMUNE SYSTEM – WHAT EVERY MDT MEMBE Immunotherapy in head and neck cancer – Current evidence and future indications	R SHOULD KNOW Kevin Harrington
15.45	Precision medicine – Utility of clinical and biomarker predictors of response for selection of immunotherapy in HNC	Gareth Thomas
16.00	Key note: Tips and tricks for the management of adverse events and complications of immunotherapeutic agents	Maura Gillison
16.30	Management of challenging cases - Recurrence and older patients	Moderator: Martin Forster
17.30	Close	